胸苷激酶1是乳腺癌、肺癌、食管癌及非霍奇金淋巴瘤患者预后及监测治疗反应的潜在标志物。
Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.
作者信息
He E, Xu X H, Guan H, Chen Y, Chen Z H, Pan Z L, Tang L L, Hu G Z, Li Y, Zhang M, Zhou J, Eriksson S, Fornander T, Skog S
机构信息
Sino-Swed Molecular Bio-Medicine Research Institute, Shenzhen, China.
出版信息
Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):352-8. doi: 10.1080/15257771003738535.
Thymidine kinase 1 (TK1) is converting thymidine to thymidine monophosphate, and is related to DNA replication and cell proliferation. The use of the TK1 protein levels as a proliferation marker in malignancies is here summarized. TK1 protein in serum (STK1p) and TK1 expression in tissues were determined by a chemoluminescent dot blot assay and by immunohistochemistry staining, respectively. The expression of TK1 in tumor tissues correlated to pathological stages and clinical grades of carcinomas (ca) of esophagus, lung and in premalignancy of breast ductal ca. STK1p could monitor the out-come of tumor therapy by being correlated to remission [breast ca, non-Hodgkin's lymphoma], relapse [breast ca] and to survival [non-Hodgkin's lymphoma] of patients. In a health screening study of 12,641 persons, STK1p seemed to predict the risk of development of neoplasia related diseases at early stage.
胸苷激酶1（TK1）可将胸苷转化为胸苷一磷酸，与DNA复制和细胞增殖有关。本文总结了将TK1蛋白水平用作恶性肿瘤增殖标志物的情况。血清中的TK1蛋白（STK1p）和组织中的TK1表达分别通过化学发光斑点印迹法和免疫组织化学染色来测定。TK1在肿瘤组织中的表达与食管癌、肺癌的病理分期和临床分级以及乳腺导管癌癌前病变相关。STK1p可通过与患者的缓解情况[乳腺癌、非霍奇金淋巴瘤]、复发情况[乳腺癌]和生存情况[非霍奇金淋巴瘤]相关来监测肿瘤治疗的结果。在一项对12641人的健康筛查研究中，STK1p似乎可以预测早期肿瘤相关疾病的发生风险。
Zotero 插件